Skip to main content
    A

    argenx NV ADR (ARGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $960.04
    -21.29 (-2.17%)

    Market Cap: $60.37B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    argenx NV ADR (ARGX) P/E Ratio & Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    argenx NV ADR (ARGX) trades at 33.5x trailing earnings and 6.1x sales. Its P/S of 6.1x is below its 5-year median of 20.9x. Its forward P/E is 28.8x. The median P/E across 6 similar companies is 24.7x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 16.3% higher over the next year. Its free cash flow yield is 3.0%.

    MultipleValue
    P/E (trailing)33.5x
    Forward P/E28.8x
    Price to sales6.1x
    Price to book178.4x
    Price to FCF33.0x
    PEG1.3
    FCF yield3.0%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 2777.4% above 6.2x.

    MultipleCurrent5-year median10-year median
    P/S6.1x20.9xN/A
    P/B178.4x6.5x6.2x
    Medians of month-end values through Oct 2026: 50 to 60 months (5-year) and 98 months (10-year).

    Valuation History

    Over the 5 of the 9 year ends shown that have a P/S, its P/S ranged from 13.1x in 2024 to 33.9x in 2022.

    Year endPriceP/SP/B
    2025$840.9514.2x6.5x
    2024$615.0013.1x7.7x
    2023$380.4325.3x4.9x
    2022$378.8333.9x7.0x
    2021$350.1922.9x6.3x
    2020$294.09N/AN/A
    2019$160.52N/A4.8x
    2018$96.07N/A4.7x
    2017$63.14N/A3.5x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    P/E history is shown only for companies that report in US dollars.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ARGX

    What is ARGX's forward P/E ratio?

    argenx NV ADR has a forward P/E ratio of 28.8x.

    Is ARGX stock overvalued?

    GNG's valuation label for ARGX is Undervalued. Its P/E of 33.5x compares with a median of 24.7x across 6 similar companies.

    What is ARGX's price to sales ratio?

    argenx NV ADR has a price to sales ratio of 6.1x.

    What is ARGX's PEG ratio?

    argenx NV ADR has a PEG ratio of 1.3.